148 related articles for article (PubMed ID: 38642470)
1. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
Kim SY; Song IC; Kim J; Kwon GC
Ann Diagn Pathol; 2024 Apr; 71():152317. PubMed ID: 38642470
[TBL] [Abstract][Full Text] [Related]
2. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Szuber N; Orazi A; Tefferi A
Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
[TBL] [Abstract][Full Text] [Related]
3. The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.
Maxson JE; Luty SB; MacManiman JD; Paik JC; Gotlib J; Greenberg P; Bahamadi S; Savage SL; Abel ML; Eide CA; Loriaux MM; Stevens EA; Tyner JW
Clin Cancer Res; 2016 Feb; 22(3):757-64. PubMed ID: 26475333
[TBL] [Abstract][Full Text] [Related]
4. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A
Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
[TBL] [Abstract][Full Text] [Related]
7. Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia.
Adam FC; Szybinski J; Halter JP; Cantoni N; Wenzel F; Leonards K; Brkic S; Passweg JR; Touw I; Maxson JE; Meyer SC
Curr Oncol; 2022 Feb; 29(2):805-815. PubMed ID: 35200567
[TBL] [Abstract][Full Text] [Related]
8. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
9. CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
Qian Y; Chen Y; Li X
Ann Hematol; 2021 Jun; 100(6):1459-1461. PubMed ID: 33822276
[TBL] [Abstract][Full Text] [Related]
10. Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Tyner JW; Gotlib J
Curr Hematol Malig Rep; 2017 Oct; 12(5):432-441. PubMed ID: 28983816
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia.
Yun JW; Yoon J; Jung CW; Lee KO; Kim JW; Kim SH; Kim HJ
J Clin Lab Anal; 2020 Feb; 34(2):e23064. PubMed ID: 31692115
[TBL] [Abstract][Full Text] [Related]
12. What's different about atypical CML and chronic neutrophilic leukemia?
Dao KH; Tyner JW
Hematology Am Soc Hematol Educ Program; 2015; 2015():264-71. PubMed ID: 26637732
[TBL] [Abstract][Full Text] [Related]
13. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice.
Tefferi A; Elliott M; Pardanani A
Curr Opin Hematol; 2015 Mar; 22(2):171-6. PubMed ID: 25575036
[TBL] [Abstract][Full Text] [Related]
14. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G; Álvarez-Larrán A; Harrison C; Martínez-Ávila JC; Hernández-Boluda JC; Ferrer-Marín F; Radia DH; Mora E; Francis S; González-Martínez T; Goddard K; Pérez-Encinas M; Narayanan S; Raya JM; Singh V; Gutiérrez X; Toth P; Amat-Martínez P; Mcilwaine L; Alobaidi M; Mayani K; McGregor A; Stuckey R; Psaila B; Segura A; Alvares C; Davidson K; Osorio S; Cutting R; Sweeney CP; Rufián L; Moreno L; Cuenca I; Smith J; Morales ML; Gil-Manso R; Koutsavlis I; Wang L; Mead AJ; Rozman M; Martínez-López J; Ayala R; Cross NCP
Blood Adv; 2023 May; 7(9):1672-1681. PubMed ID: 36375042
[TBL] [Abstract][Full Text] [Related]
15. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
Dao KH; Solti MB; Maxson JE; Winton EF; Press RD; Druker BJ; Tyner JW
Leuk Res Rep; 2014; 3(2):67-9. PubMed ID: 25180155
[TBL] [Abstract][Full Text] [Related]
16.
Kwon A; Ibrahim I; Le T; Jaso JM; Weinberg O; Fuda F; Chen W
Leuk Res Rep; 2022; 17():100323. PubMed ID: 35586707
[TBL] [Abstract][Full Text] [Related]
17. CSF3R truncation mutations in a patient with B-cell acute lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib.
Schwartz MS; Wieduwilt MJ
Leuk Res Rep; 2020; 14():100208. PubMed ID: 32577374
[TBL] [Abstract][Full Text] [Related]
18. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
19. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
20. Myeloid Disease with the CSF3R T618I Mutation after CLL.
Couto ME; Bizarro S; Sousa D; Domingues N; Oliveira I; Martins G; Teixeira MR; Mariz M
Case Rep Hematol; 2020; 2020():6670965. PubMed ID: 33414971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]